BC Innovations | Jun 14, 2012
Distillery Therapeutics

Indication: Cancer

Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Brain cancer Inducible nitric oxide synthase 2 (NOS2; iNOS); epidermal growth factor receptor variant III (EGFRvIII) In vitro and mouse studies suggest iNOS inhibitors could...
BC Innovations | May 7, 2009
Distillery Therapeutics

Indication: Neurology

This week in therapeutics Indication Target/marker/pathway Summary Licensing status Publication and contact information Neurology Pain Nitric oxide synthase 2 (inducible) (NOS2; iNOS) In vitro and mouse studies identified quinolinone small molecule inhibitors of iNOS that...
BC Innovations | May 7, 2009
Distillery Therapeutics

Indication: Neurology

This week in therapeutics Indication Target/marker/pathway Summary Licensing status Publication and contact information Neurology Pain Nitric oxide synthase 2 (inducible) (NOS2; iNOS) In vitro and mouse studies identified quinolinone small molecule inhibitors of iNOS that...
BC Week In Review | Sep 8, 2008
Clinical News

EpiStem, Rottapharm S.p.A. preclinical data

In vitro studies of CR 3294, an inducible nitric oxide synthase ( iNOS ) and matrix metalloproteinase (MMP) co-inhibitor, showed that it protected small intestinal crypts from cytotoxic insult of common chemotherapy agents such as 5-FU. Rottapharm...
Items per page:
1 - 4 of 4